Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematology
•
Endocrinology
•
Diabetes
•
Primary Care
Do you routinely monitor INR when starting GLP1 R agonist therapy on patients taking warfarin?
Related Questions
Do you prioritize dietary modifications and exercise over early pharmacologic interventions, such as metformin or insulin, for women diagnosed with gestational diabetes?
How would you counsel a female to male transgender patient regarding VTE risk with testosterone therapy, who has additional mild-moderate risk factors for thrombosis?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
What is the recommended frequency and duration of exercise bouts in order to sustain the beneficial effects of exercise on insulin sensitivity?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
When would you treat mild anemia from low testosterone in an older male?
